Corcept Therapeutics Inc. to Announce Second Quarter 2013 Financial Results and Host Conference Call

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MENLO PARK, CA--(Marketwired - August 01, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter 2013 financial results on August 8, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-888-771-4371 from the United States or +1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 35403018.

A replay will be available through August 22, 2013 at 1-888-843-7419 from the United States and
+1-630-652-3042 internationally. The passcode is 35403018.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. Korlym, a first generation competitive GR-II antagonist, is the company’s first FDA-approved medication. The company has a phase 3 trial underway for mifepristone for treatment of the psychotic features of psychotic depression and a portfolio of selective GR-II antagonists that competitively block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR-II antagonists, including mifepristone, in the treatment of a wide variety of metabolic, psychiatric and other disorders. It also holds composition of matter patents for its selective GR-II antagonists.


CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
Email Contact
www.corcept.com

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC